Table 1 Review of literature depicting case reports and series of cyproheptadine-induced liver injury
Study | Age/sex | Indication | Dosage | Pattern of liver injury | Potential confounders | Temporal evolution |
|---|---|---|---|---|---|---|
Henry et al. [5] | 25/F | Pruritus | 12 mg/day | Cholestatic | None | Onset of jaundice after drug initiation: 1 month; Resolution of jaundice after drug discontinuation: 2 months |
Larrey et al. [3] | 23/F | Anorexia | 12 mg/day | Cholestatic | Acetylsalicylic acid, ethinylestradiol, quingestrone | Onset of jaundice after drug initiation: 5 days; Resolution of jaundice after drug discontinuation: 3 weeks |
Freneaux et al. [6] | Adult (NA) | Appetite stimulation | 8 mg/day | Cholestatic | Dihydroergocristine, magnesium + pyridoxine, methionine + cysteine | Onset of jaundice after drug initiation 1 month; Resolution of jaundice after drug discontinuation: 3 months |
Chertoff et al. [2] | 55/F | Appetite stimulation | NA | Acute liver failure | None | Onset of jaundice after drug initiation: 3 weeks; Resolution of jaundice after drug discontinuation: 3 weeks |
Garland et al. [7] | 40/F | “Figure enhancer” | NA | Drug-induced autoimmune hepatitis (hepatocellular) | Lysine, alcohol | Onset of jaundice after drug initiation: 6 weeks; Resolution of jaundice after drug discontinuation: 3 months |
Bertrand et al. [1] | 15 patients (1–94 years) | Orexigenic in 2 Non available in 13 | Ranging from 4 to 12 mg/day | Hepatocellular, cholestatic, acute liver failure in 3 | - | - |
Our case | 20/M | Orexigenic | 20 mg | Cholestatic | Chronic hepatitis B | Onset of jaundice after drug initiation: 3 months; Resolution of jaundice after drug discontinuation: 2 months |